Form 4: Bausch + Lomb Exec Acquires 17,715 Shares

Bausch + Lomb's EVP of R&D and CMO, Yehia Hashad, acquired 17,715 common shares through the vesting of performance stock units.

Summary

• Yehia Hashad, Executive Vice President of Research & Development and Chief Medical Officer of Bausch + Lomb Corporation (BLCO), acquired 17,715 common shares.
• The acquisition occurred on August 5, 2025, at a price of $0 per share, indicating it was an award or grant.
• These shares represent common stock underlying Performance Stock Units (PSUs) originally granted on March 1, 2023, under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan.
• The PSUs satisfied the applicable performance conditions at the target performance level (100%) as of August 5, 2025.
• The earned PSUs are scheduled to vest on March 1, 2026, subject to Mr. Hashad's continued employment through that date.
• Following this transaction, Mr. Hashad beneficially owns 134,454 common shares directly.

Sentiment

Score: 7

Explanation: The acquisition of shares by a key executive through the successful vesting of performance-based awards is generally a positive signal, indicating that the company met its internal performance targets and that executive compensation is aligned with shareholder interests.

Positives

• Management's compensation is directly tied to company performance through performance stock units, aligning executive interests with shareholder value.
• The PSUs met their target performance conditions, indicating the company achieved specific internal goals.
• Increased direct ownership by a key executive, which can signal confidence in the company's future.

Risks

• The vesting of the earned PSUs on March 1, 2026, is contingent upon the reporting person's continued employment through that date.

Future Outlook

The earned Performance Stock Units are scheduled to vest on March 1, 2026, contingent upon the reporting person's continued employment through that date.

Industry Context

This transaction is a routine executive compensation event, common across publicly traded companies in various sectors, including the pharmaceutical and medical device industries. It reflects the company's internal compensation structure and the achievement of specific performance targets rather than broader industry trends or competitive shifts.

Comparison to Industry Standards

• Performance-based equity awards, such as Performance Stock Units (PSUs), are a standard component of executive compensation packages in the pharmaceutical and medical device industries. This practice aligns executive incentives with company performance and shareholder value, consistent with global benchmarks for corporate governance and compensation.
• No specific comparable companies, projects, or results are detailed in the filing to allow for a direct quantitative comparison.

Stakeholder Impact

• Shareholders: The transaction demonstrates alignment of executive incentives with company performance, as the PSUs met their target conditions, potentially benefiting shareholders through improved company results.
• Employees: This event highlights the company's executive compensation framework, which may influence broader employee compensation strategies and morale.

Next Steps

• The earned Performance Stock Units are scheduled to vest on March 1, 2026, subject to the reporting person's continued employment.

Key Dates

Recommendation

This Form 4 filing details a routine, pre-scheduled executive compensation event where performance stock units vested. While it indicates the company met certain performance targets, it does not provide new material information about the company's financial health, strategic direction, or market position that would warrant a change in investment recommendation. It primarily confirms the execution of an existing compensation plan.

Keywords

Bausch + Lomb, BLCO, Insider Trading, Form 4, Performance Stock Units, Executive Compensation, Share Acquisition, Pharmaceuticals, Medical Devices